Ascendis Pharma A/S (NASDAQ:ASND) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report sent to investors on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $173.00 price objective on the biotechnology company’s stock.

Several other equities research analysts also recently issued reports on the company. Wedbush increased their price objective on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an outperform rating in a research note on Thursday, February 8th. Jefferies Financial Group initiated coverage on Ascendis Pharma A/S in a research note on Wednesday, December 20th. They set a buy rating and a $150.00 price target for the company. JPMorgan Chase & Co. raised their price target on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an overweight rating in a research note on Tuesday, April 2nd. Wells Fargo & Company raised their price target on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an overweight rating in a research note on Friday, March 15th. Finally, StockNews.com raised Ascendis Pharma A/S from a sell rating to a hold rating in a research note on Monday, December 25th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $173.25.

Ascendis Pharma A/S Stock Down 0.9 %

Shares of ASND stock opened at $140.89 on Thursday. The stock has a 50-day simple moving average of $149.20 and a 200 day simple moving average of $123.87. Ascendis Pharma A/S has a fifty-two week low of $66.03 and a fifty-two week high of $161.00. The stock has a market capitalization of $8.20 billion, a P/E ratio of -15.23 and a beta of 0.50.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. The business had revenue of $148.62 million during the quarter, compared to analyst estimates of $97.02 million. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post -4.19 earnings per share for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $25,000. Private Ocean LLC acquired a new stake in shares of Ascendis Pharma A/S during the first quarter worth $36,000. US Bancorp DE grew its stake in shares of Ascendis Pharma A/S by 35.2% during the fourth quarter. US Bancorp DE now owns 284 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 74 shares during the period. Quadrant Capital Group LLC grew its stake in Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 151 shares during the period. Finally, EverSource Wealth Advisors LLC grew its stake in Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 91 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.